Compliance with herpes zoster vaccination in young and adult individuals in two regions of Italy

详细信息    查看全文

• 作者：Antonino Parlato (1)
  Vincenzo Romano Spica (2)
  Massimo Ciccozzi (3)
  Francesca Farchi (3)
  Francesca Gallè (4)
  Valeria Di Onofrio (4)
  Elisabetta Franco (5)
  Giorgio Liguori (4)
  
• 刊名：BMC Public Health
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：10
• 期：1
• 全文大小：428KB
• 参考文献：1. Weinberg JM: Herpes zoster: epidemiology, natural history, and common complications. / J Am Acad Dermatol 2007, 57:S130-S135. CrossRef
  2. Hope-Simpson RE: The nature of herpes zoster: a long term study and a new hypothesis. / Proc R Soc Med 1965, 58:9-0.
  3. Ragozzino MW, Melton LJ, Kurland LT, Chu CP, Perry OH: Population-based study of herpes zoster and its sequelae. / Medicine 1982,61(5):310-16. CrossRef
  4. Brisson M, Edmunds WJ, Law B, / et al.: Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. / Epidemiol Infect 2001, 127:305-14. CrossRef
  5. Thomas SL, Hall AJ: What does epidemiology tell us about risk factors for herpes zoster? / Lancet Infect Dis 2004, 4:26-3. CrossRef
  6. Volpi A, Gross G, Hercogova J, Johnson RW: Current management of herpes zoster. The European view. / Am J Clin Dermatol 2995,6(5):317-25. CrossRef
  7. Brisson M, Edmunds WJ: Epidemiology of Varicella-Zoster virus in England and Wales. / J Med Virol 2003, 14:70-9.
  8. Weaver BA: The Burden of Herpes Zoster and Postherpetic Neuralgia in the United States. / JAOA 2007,107(1):2-.
  9. Oxman MN, Levin MJ, Johnson GR, Shingles Prevention Study Group, / et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. / N Engl J Med 2005, 352:2271-4. CrossRef
  10. Simberkoff MS, Arbeit RD, Johnson GR, / et al.: Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. / Ann Intern Med 2010,152(9):545-4.
  11. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA: The incidence of herpes zoster in a United States administrative database. / J Gen Intern Med 2005, 20:748-53. CrossRef
  12. Coplan P, Black S, Rojas C, / et al.: Incidence and hospitalization rates of varicella and herpes zoster before varicella vaccine introduction: a baseline assessment of the shifting epidemiology of varicella disease. / Pediatr Infect Dis J 2001, 20:641-45. CrossRef
  13. Dworkin RH, Schmader KE: Epidemiology and natural history of herpes zoster and postherpetic neuralgia. In / Herpes zoster and postherpetic neuralgia. Edited by: Watson CPN, Gerhon AA. New York: Elsevier Press; 2001:39-4.
  14. Schmader K, Gnann JW Jr, Watson CP: The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. / J Infect Dis 2008,197(1):207-5. CrossRef
  15. Gil A Sanmartin M, Carrasco P, Gonzales A: Epidemiology of severe varicella-zoster virus infection in Spain. / Vaccine 2004, 22:3947-1. CrossRef
  16. Di Legami V, Gianino MM, Atti MC, Massari M, Migliardi A, Tomba GS, Zotti C, Zoster Study Group: Epidemiology and costs of herpes zoster: background data to estimate the impact of vaccination. / Vaccine 2007,25(43):7598-04. CrossRef
  17. Creed R, Satyaprakash A, Ravanfar P: Varicella zoster vaccines. / Dermatol Ther 2009,22(2):143-. CrossRef
  18. Mitka M: FDA approve Schingles Vaccine - Herpes Zoster Vaccine targets older adults. / Medical News and Perspectives 2006, 296:157.
  19. Pellissier JM, Brisson M, Levin MJ: Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. / Vaccine 2007, 25(49):8326-7. CrossRef
  20. Harpaz R, Ortega-Sanchez IR, Steward JF: Prevention of Herpes Zoster. Recommendations of the Advisory Committee on Immunization Practices (ACIP). / MMWR 2008, 57:1-0.
  21. Marino MG, Bagnato B, Torella I, Franco E: Active immunoprophylaxis to reduce clinical impact of Herpes Zoster and its complications. / Ig Sanita Pubbl 2009,65(3):299-11.
  22. Reynolds MA, Chaves SS, Harpaz R, Lopez AS, Seward JF: The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. / J Infect Dis 2008,197(1):224-. CrossRef
  23. Gershon AA, Katz SL: Perspective on live varicella vaccine. / J Infect Dis 2008,197(2):242-. CrossRef
  24. Hambleton S: Prevention of varicella and zoster by live attenuated VZV vaccine. / Front Biosc 2008, 13:2696-04. CrossRef
  25. Betts RF: Vaccination strategies for the prevention of Herpes zoster and postherpetic neuralgia. / J Am Acad Dermatol 2007,57(6):143-. CrossRef
  26. Levin MJ, Shmader K: Prevention strategies: herpes zoster, post-herpetic neuralgia and immunogenicity. / Herpes 2007,14(2):45-.
  27. Gnann JW: Vaccination to prevent herpes zoster in older adults. / J Pain 2008,9(1):31-. CrossRef
  28. Gelb LD: Preventing herpes zoster through vaccination. / Ophtalmology 2008,115(2):35-. CrossRef
  29. Franco E, Zaratti L, Ambrosini Spinella S: It is possible to prevent herpes zoster through vaccination? / Ig San Pubbl 2007,63(2):191-.
  30. Lieu TA, Ortega-Sanchez I, Ray GT, / et al.: Community and patient values for preventing herpes zoster. / Pharmacoeconomics 2008,26(3):235-9. CrossRef
  31. Adams EN, Parnapy S, Bautista P: Herpes zoster and vaccination: a clinical review. / Am J Health Syst Pharm 2010,67(9):724-. CrossRef
  32. Moore L, Remy V, Martin M, Beillat M, McGuire A: A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. / Cost Eff Resour Alloc 2010,8(1):7. CrossRef
  33. Hambleton S, Gershon AA: The impact of varicella vaccination in the United States. / Semin Pediatr Infect Dis 2005, 16:38-3. CrossRef
  34. Hicks LD, Cook-Norris RH, Mendoza N, Madkan V, Arora A, Tyring S: Family history as risk factor for herpes zoster. / Arch Dermatol 2008,144(5):603-. CrossRef
  35. Kerzner B, Murray AV, Cheng F, / et al.: Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. / J Am Geriatr Soc 2007,55(10):1499-07. CrossRef
  36. Cunningham AL, Breuer J, Dwyer DE, / et al.: The prevention and management of herpes zoster. / Med J Aust 2008,188(3):171-.
  37. Paek E, Johnson R: Public Awareness and Knowledge of Herpes Zoster: Results of a Global Survey. / Gerontology 2010,56(1):20-1. CrossRef
  38. Opstelten W, van Essen GA, Hak E: Determinants of non-compliance with herpes zoster vaccination in the community-dwelling elderly. / Vaccine 2009,27(2):192-.
  39. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2458/10/333/prepub
  
• 作者单位：Antonino Parlato (1)
  Vincenzo Romano Spica (2)
  Massimo Ciccozzi (3)
  Francesca Farchi (3)
  Francesca Gallè (4)
  Valeria Di Onofrio (4)
  Elisabetta Franco (5)
  Giorgio Liguori (4)
  
  1. Epidemiology and Prevention Departmental Area, Local Health Agency NA2, Via Corrado Alvaro 8, 80074, Pozzuoli (Naples), Italy
  2. Department of Health Sciences, University of Rome "Foro Italico", Piazza Lauro de Bosis 3, 00135, Rome, Italy
  3. Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità (ISS), Viale Regina Elena 299, 00161, Rome, Italy
  4. Department of Studies of Institutions and Territorial Systems, University of Naples "Parthenope", Via Medina 40, 801331, Naples, Italy
  5. Department of Public Health, Faculty of Medicine, University of Rome "Tor Vergata", Via di Tor Vergata 135, 00173, Rome, Italy
  
• ISSN：1471-2458

文摘

Background The purpose of this work was to explore the knowledge and acceptance of Varicella Zoster Virus (VZV)-Herpes Zoster (HZ) vaccination in the general Italian population, where the HZ vaccine has not yet been distributed, using a prevalence study of subjects from two regions in Italy. Methods A group of 3,173 individuals were interviewed using a questionnaire. The youngest age group (?20 year) was composed of students interviewed at university. The middle age group (21-40 years) and the older age group (?41 years) were interviewed by general practitioners in their office. Results In both regions, the majority of subjects had been infected with varicella, and only 165 (5.2%) subjects reported receiving the VZV vaccination. Regarding HZ, 2,749 (86.6%) individuals stated that they knew of the virus and 2,233 (70%) were willing to be vaccinated against HZ. The majority of people willing to be vaccinated were in the middle and older age groups (36.6% and 44.7%, respectively). Conclusion Compliance versus vaccination results were satisfactory and probably, with the upcoming availability of the HZ vaccine in Italy, adults will be favourably disposed towards vaccination.